Aplastic Anemia Market Size, Share, and Industry Analysis, By Drug Class (Selective Immunosuppressants, Platelet-stimulating Agents, and Others), By Drug Type (Biologics and Non-Biologics), By Disease Type (Acquired Aplastic Anemia and Inherited Aplastic Anemia), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Aplastic anemia is a rare and serious blood disorder where the bone marrow fails to produce sufficient blood cells, leading to a deficiency in the red blood cells, white blood cells, and platelets. The condition can occur at any age but is more common among teenagers, young adults, and older adults. The symptoms of this disease include fatigue, pale skin, rash, dizziness, headache, nosebleeds, fever, and bloody stool.

The risk factors for such disease include smoking, family history, exposure to ionizing radiation, autoimmune disorders, exposure to chemicals, chemotherapy, and viral infections. The disease can be diagnosed through bone marrow biopsy, blood tests, and physical examination.

The market growth is primarily attributed to the higher burden of aplastic anemia across the globe. This is expected to increase the demand for the treatment of such conditions, thereby driving the market growth in the coming years.

• For instance, according to an article published by the Thalassaemia International Federation in June 2024, an observational study at 7 Spanish hospitals from 2010 to 2019 reported that, despite being a rare condition and therapeutic advancements in its treatment, the burden of aplastic anemia is still high for healthcare systems due to the high morbidity of disease.

Furthermore, this significant burden of the disease is mainly attributed to the increase in the number of radiation and chemotherapy treatments for cancer patients. These therapies act by killing the cancer cells along with stem cells in the bone marrow, increasing the risk of aplastic anemia. This is expected to surge the demand for treatment of such conditions, thereby propelling the market growth.

The high burden is further increasing awareness and fueling the diagnosis rates of such conditions, which, in turn, is anticipated to boost the demand for treatment with drugs, thereby driving the market growth in the forthcoming years.

The COVID-19 pandemic had a significant impact on the aplastic anemia market in 2020. The pandemic led to increased awareness and diagnosis rates of aplastic anemia, particularly in patients with severe cases who were more susceptible to serious infections such as COVID-19. This fueled the demand for treatment of such conditions, contributing to the market growth during the pandemic.

Segmentation

Key Insights

The report covers the following key insights:

• Incidence of Key Diseases, By Key Countries/Region, 2023
• New Product Approvals By Key Players
• Pipeline Analysis By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships)
• Impact of COVID-19 on the Market  

Analysis by Disease Type

Based on the disease type, the market is divided into acquired aplastic anemia and inherited aplastic anemia. The acquired aplastic anemia segment is projected to account for a significant share of the global aplastic anemia market during the forecast period. The growth of this segment is attributed to a high incidence of this disease compared to inherited aplastic anemia. This growth in the incidence is primarily attributed to factors such as the infection caused by viruses, such as the human immune virus (HIV) or Epstein-Barr virus, the usage of certain medications that kill stem cells in the bone marrow, and exposure to radiation and chemotherapy treatment for cancers. This is expected to fuel the segment growth during the forecast period.

• For instance, according to an article published by the International Journal of Hematology in February 2024, a surveillance study in Barcelona reported an incidence of aplastic anemia of 2.34 per million inhabitants annually.

On the other hand, the inherited aplastic anemia segment is anticipated to grow at a substantial CAGR during the forecast period. The growth of the segment is attributed to the rising incidence of aplastic anemia among children but slower than that of acquired aplastic anemia. For instance, as per the data published by WebMD LLC in March 2023, inherited causes of aplastic anemia are responsible for at least 25% of cases in children. This is expected to boost the treatment demand for inherited aplastic anemia, driving segmental growth.

Regional Analysis

To gain extensive insights into the market, Download for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to hold a significant share of the aplastic anemia market during the forecast period. The market growth is primarily attributed to the rising prevalence of autoimmune disorders in this region. The autoimmune condition attacking the body’s immune system also involves stem cells in the bone marrow, resulting in aplastic anemia. In addition, medications such as disease-modifying antirheumatic drugs (DMARDs) used in the treatment of rheumatoid arthritis (RA) may cause folate deficiency, which increases the risk of aplastic anemia, contributing to the rising prevalence. This is expected to boost the demand for aplastic anemia in the region, thereby driving market growth.

• For instance, according to the data published by the Centers for Disease Control and Prevention in February 2024, a National Health Interview Survey reported that the age-adjusted prevalence of diagnosed arthritis in U.S. adults aged 18 and more was 18.9%, with men (16.1%) and women (21.5%) in 2022.

Asia Pacific is projected to grow at a significant CAGR during the forecast timeframe. The growth of the region is mainly attributed to the increasing exposure to toxic chemicals used in pesticides and insecticides in the region. The harmful ingredients present in such chemicals are linked to aplastic anemia, which is increasing the significant burden of disease in the region. This is further driving the awareness for diagnosis and treatment of aplastic anemia in the region, which is anticipated to augment the market growth.

Key Players Covered

The market consists of significant players, such as Teva Pharmaceuticals, Solvay, Pfizer, Inc., Kyowa Kirin Co., Ltd., Novartis AG, GSK, Sanofi, Baxter, Partner Therapeutics, Inc., and Amgen Inc. These key players' significant product approvals are expected to fuel their revenue growth.

Key Industry Developments

• In February 2024, researchers at the University of Massachusetts Amherst announced the release of a first-of-a-kind study that focused on aplastic anemia treatment. This study identified a specific enzyme called PRMT5 as the key regulator of ‘suppressive activity in a specialized population of cells’.
• In December 2023, Teva Pharmaceuticals received FDA approval for its Allvaiz to treat chronic immune thrombocytopenia (ITP), thrombocytopenia in adult patients with chronic hepatitis C, and severe aplastic anemia in adults.
• In June 2019, Kyowa Kirin Co., Ltd. received the partial change approval of Romiplate for an additional indication of treatment of aplastic anemia (AA).